Erratum to: A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia (International Journal of Hematology (2013) 98, (164-170) DOI: 10.1007/s12185-013-1393-x);A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

International Journal of Hematology

Volumn 98, Issue 2, 2013, Pages 164-170

  Ogawa, Yoshiaki ^a   Ogura, Michinori ^b   Suzuki, Tatsuya ^b   Ando, Kiyoshi ^a   Uchida, Toshiki ^b   Shirasugi, Yukari ^a   Tobinai, Kensei ^c   Lee, Je Hwan ^d   Kase, Masazumi ^e   Katsura, Koichi ^e   Hotta, Tomomitsu ^f  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d Asan Medical Center   (South Korea)

^e Development and Medical Affairs Division   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Ofatumumab; Phase I II study; Relapsed or refractory chronic lymphocytic leukemia

Indexed keywords

CETIRIZINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; OFATUMUMAB; PARACETAMOL; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ELECTROCORTICOGRAPHY; ENTERITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INFLUENZA; INFUSION RELATED REACTION; JAPANESE; KOREA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA RELAPSE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSITIONAL VERTIGO; PROPHYLAXIS; RASH; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SIDE EFFECT; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; TREATMENT REFUSAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

AGED; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; JAPAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; REPUBLIC OF KOREA;

EID: 84882255958     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1491-9     Document Type: Erratum

References (15)

1. Teeling JL, French RR, Cragg MS, von den Brakel JH, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793-800.
2. Teeling JL, Mackus WJ, Wiegman LJ, von den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362-71.
3. Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181:822-32.
4. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewsk J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486-95.
5. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010;28:3525-30.
6. Coiffier B, Losic N, Rønn BB, Lepretre S, Pedersen LM, Gadeberg O, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol. 2010;150:58-71.
7. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117:6450-8.
8. Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Österborg A. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118:5126-9.
9. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119:3698-704.
10. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094-100.
11. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749-55.
12. Ogura M, Hatake K, Tobinai K, Uchida T, Suzuki T, Terui Y, et al. Phase 1 study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Jpn J Clin Oncol. 2013;43:466-75.
13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia on Chronic Lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-56.
14. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical studies in this patient population. Cancer. 2002;94:2033-9.
15. Österborg A, Rønn BB, Jewell RC, Kipps TJ, Mayer J, Stilgenbauer S, et al. Correlation between serum ofatumumab concentrations, baseline patient characteristics, and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab. Blood (ASH Annual Meeting Abstracts). 2009;114:3433.